Researchers found that maternal anti-αIIb antibodies directly target fetal hematopoietic stem cells (HSCs), leading to impaired fetal liver hematopoiesis, disrupted liver development and early pregnancy loss in a murine model of fetal and neonatal alloimmune thrombocytopenia (FNAIT), according to a recent study published in Blood.
Maternal anti-αIIb antibodies cause a severe form of FNAIT by attacking fetal hematopoietic stem cells, resulting in profound hematopoietic failure and frequent miscarriage. Although anti-β3 (HPA-1a) antibodies account for 80–90% of reported FNAIT cases, anti-αIIb antibodies are rare (2–3%) yet associated with severe bleeding and pregnancy loss.
FNAIT is caused by maternal IgG alloantibodies crossing the placenta and targeting paternally inherited HSCs. Current management for diagnosed cases includes intravenous immunoglobulin (IVIG) or neonatal Fc receptor (FcRn) blockade to reduce antibody effects, but prenatal screening for anti-platelet antibodies is not routinely performed.
“Anti-αIIb FNAIT led to miscarriage in 66% of pregnancies, twice the rate seen in anti-β3 FNAIT (p<0.02),” the authors wrote.
The authors aimed to evaluate why anti-αIIb-mediated FNAIT cases are rare yet clinically severe by developing a murine model in which αIIb-knockout females were immunized against αIIb to generate specific antibodies, then bred with wild-type or heterozygous males to assess antibody effects on αIIb-expressing fetuses, to determine whether these antibodies directly target HSCs and cause early hematopoietic disruption and pregnancy loss.
The outcomes included an almost 70% miscarriage rate (twice that of anti-β3 models), reduced fetal liver size, depleted LSK hematopoietic stem/progenitor cells and specific multipotent progenitor subsets, downstream loss of myeloid cells, macrophages, and megakaryocytes, and genotype-specific effects confirming direct antibody targeting of αIIb-expressing cells.
To improve future research, the study could be strengthened by longer-term follow-up of surviving pups, broader immunological profiling or complementary in vitro human HSC assays to enhance translational relevance.
“Our findings demonstrate that maternal anti-αIIb antibodies induce a severe, previously unrecognized form of FNAIT in which fetal HSCs are directly targeted, leading to impaired fetal liver hematopoiesis, disrupted liver development, and early pregnancy loss. Unlike anti-β3-mediated FNAIT, which typically presents postnatally through thrombocytopenia and/or bleeding diatheses, anti-αIIb antibodies act earlier on αIIb-expressing progenitors, resulting in fetal demise,” the authors concluded.
Sign up here to get the latest news, perspectives, and information about FNAIT sent directly to your inbox. Registration is free and only takes a minute.
